Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial

Abstract

Early-stage TNBC might be a target population for olaparib, irrespective of g<i>BRCA</i> mutations. Future trials should combine TILs, PD-L1 and g<i>BRCA</i> status to better identify candidates for escalated/de-escalated treatment strategies including olaparib.